These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 7675145)

  • 1. [Clinical studies of adjuvant systemic chemotherapy in breast cancer in The Netherlands assumes a greater number of patients than is available].
    Blijham GH
    Ned Tijdschr Geneeskd; 1995 Aug; 139(31):1599-602. PubMed ID: 7675145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical study of adjuvant systemic chemotherapy in breast cancer in The Netherlands assumes a greater number of patients than is available].
    Gaasbeek Janzen HM; Eliel M
    Ned Tijdschr Geneeskd; 1995 Oct; 139(41):2111. PubMed ID: 7477573
    [No Abstract]   [Full Text] [Related]  

  • 3. Adjuvant therapy for breast cancer.
    NIH Consens Statement; 2000 Nov 1-3; 17(4):1-35. PubMed ID: 11512506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Adjuvant systemic therapy for patients with resectable breast cancer: guideline from the Dutch National Breast Cancer Platform and the Dutch Society for Medical Oncology].
    Bontenbal M; Nortier JW; Beex LV; Bakker P; Hupperets PS; Nooij MA; van Veelen H; Vreugdenhil G; Richel DJ; Blijham GH
    Ned Tijdschr Geneeskd; 2000 May; 144(21):984-9. PubMed ID: 10858788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The importance of steroid receptors for the prognosis and hormone treatment of breast cancer patients: a retrospective study in Southeastern Netherlands].
    Voogd AC; Crommelin MA; Repelaer van Driel OJ; Tutein Nolthenius-Puylaert MC; Vreugdenhil G; Coebergh JW
    Ned Tijdschr Geneeskd; 1998 Aug; 142(31):1772-8. PubMed ID: 9856143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Substantial increase in the use of adjuvant systemic treatment for early stage breast cancer reflects changes in guidelines in the period 1990-2006 in the southeastern Netherlands.
    Sukel MP; van de Poll-Franse LV; Nieuwenhuijzen GA; Vreugdenhil G; Herings RM; Coebergh JW; Voogd AC
    Eur J Cancer; 2008 Sep; 44(13):1846-54. PubMed ID: 18640030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low locoregional recurrence rate among node-negative breast cancer patients with tumors 5 cm or larger treated by mastectomy, with or without adjuvant systemic therapy and without radiotherapy: results from five national surgical adjuvant breast and bowel project randomized clinical trials.
    Taghian AG; Jeong JH; Mamounas EP; Parda DS; Deutsch M; Costantino JP; Wolmark N
    J Clin Oncol; 2006 Aug; 24(24):3927-32. PubMed ID: 16921044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in management techniques and patterns of disease recurrence over time in patients with breast carcinoma treated with breast-conserving therapy at a single institution.
    Pass H; Vicini FA; Kestin LL; Goldstein NS; Decker D; Pettinga J; Ingold J; Benitez P; Neumann K; Rebner M; Dekhne N; Martinez A
    Cancer; 2004 Aug; 101(4):713-20. PubMed ID: 15305400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor angiogenesis predicts clinical outcome of node-positive breast cancer patients treated with adjuvant hormone therapy or chemotherapy.
    Gasparini G; Barbareschi M; Boracchi P; Verderio P; Caffo O; Meli S; Dalla Palma P; Marubini E; Bevilacqua P
    Cancer J Sci Am; 1995; 1(2):131-41. PubMed ID: 9166466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumour epidermal growth factor receptor, erbB-2 and cathepsin D in node-negative invasive breast cancer: their impact on the selection of patients for systemic adjuvant therapy.
    Tonkin KS; McKay JW; Stitt LW; Tokmakejian S; Haines DS
    Cancer Prev Control; 1999 Apr; 3(2):131-6. PubMed ID: 10474760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical analysis of resectable breast cancer: a report of 6 263 cases].
    Yang MT; Rong TH; Huang ZF; Zeng CG; Long H; Fu JH; Lin P; Wang X; Wang SY; Wang X; Tang J
    Ai Zheng; 2005 Mar; 24(3):327-31. PubMed ID: 15757535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
    Mariotto AB; Feuer EJ; Harlan LC; Abrams J
    J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
    Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
    Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy.
    Lin YC; Chen SC; Chang HK; Hsueh S; Tsai CS; Lo YF; Hwang TL; Chen MF
    Jpn J Clin Oncol; 2005 Sep; 35(9):514-9. PubMed ID: 16199422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of chemotherapy for node-negative breast cancer.
    Cooper MR
    Cancer; 1991 Mar; 67(6 Suppl):1744-7. PubMed ID: 2001570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort.
    Elkin EB; Hurria A; Mitra N; Schrag D; Panageas KS
    J Clin Oncol; 2006 Jun; 24(18):2757-64. PubMed ID: 16782916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ten year follow-up results of patients with carcinoma of the breast in a co-operative clinical trial evaluating surgical adjuvant chemotherapy.
    Fisher B; Slack N; Katrych D; Wolmark N
    Surg Gynecol Obstet; 1975 Apr; 140(4):528-34. PubMed ID: 805475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prognostic benefits evaluated: new guidelines for systemic adjuvant therapy for axillary node-negative breast cancer vs. implementation of sentinel node biopsy procedure].
    Roumen RM
    Ned Tijdschr Geneeskd; 2000 May; 144(21):980-4. PubMed ID: 10858787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
    Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M
    Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Systemic adjuvant therapy of breast cancer: myths and controversies].
    Roy JA; Piccart MJ
    Rev Med Brux; 1996 Sep; 17(4):267-70. PubMed ID: 8927859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.